| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 23.91 | 23.91 | 23.91 | 23.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,530.7 | 9,325.94 | 8,719.75 | 7,601.84 |
Net Worth | 10,554.61 | 9,349.85 | 8,743.66 | 7,625.75 |
Minority Interest | ||||
Debt | 1,005.21 | 1,181.69 | 2,293.78 | 1,383.51 |
Deferred Tax Liability Net | 253.55 | 207.82 | 199.92 | 189.08 |
Total Liabilities | 11,813.37 | 10,739.36 | 11,237.36 | 9,198.34 |
Fixed Assets | 1,873.02 | 2,053.84 | 2,114.52 | 2,081.62 |
Intangible Assets | ||||
Investments | 2,828.98 | 3,005.55 | 2,528.61 | 2,152.38 |
Deferred Tax Asset Net | 1,540.21 | 1,292.74 | 1,248.66 | 1,143.51 |
Networking Capital | 4,505.31 | 2,223.36 | 3,048.36 | 2,147.47 |
Inventories | 1,849.56 | 1,724.66 | 1,975.73 | 1,513.26 |
Inventory Days | 81.67 | 76.5 | ||
Sundry Debtors | 1,753.64 | 1,768.34 | 1,768.22 | 1,556.55 |
Debtor Days | 73.09 | 78.69 | ||
Other Current Assets | 3,380.09 | 930.04 | 1,436.14 | 841.13 |
Sundry Creditors | -1,570.94 | -1,076.34 | -1,111.02 | -952.92 |
Creditor Days | 45.92 | 48.17 | ||
Other Current Liabilities | -907.04 | -1,123.34 | -1,020.71 | -810.55 |
Cash | 1,065.85 | 2,163.87 | 2,297.21 | 1,673.36 |
Total Assets | 11,813.37 | 10,739.36 | 11,237.36 | 9,198.34 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
